{"url_path":"/sec/kalv/8-k/2026-06-11/item-5-01","section_key":"item-5-01","section_title":"Item 5.01 Changes in Control of Registrant.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1348911/0001140361-26-024949-index.html","accession_number":"0001140361-26-024949","cik":"0001348911","ticker":"KALV","issuer_name":"KalVista Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1348911/0001140361-26-024949-index.html","primary_entity_key":"0001348911","primary_entity_name":"KalVista Pharmaceuticals, Inc."},"word_count":100,"has_tables":true,"body_markdown":"Item 5.01\n\nChanges in Control of Registrant.\n\nThe disclosures under the Introductory Note, Item 3.01, Item 5.02 and Item 5.03 are incorporated herein by reference.\n\nAs a result of the consummation of the Offer and the Merger, there was a change in control of the Company, and Parent, as the direct parent of Purchaser,\nacquired control of the Company. To the knowledge of the Company, there are no arrangements which may at a subsequent date result in a further change in control of the Company.\n\nThe merger consideration was funded through a combination of Parent’s cash on hand and financing."}